BBIO
BridgeBio Pharma, Inc.
BBIO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
BBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
BBIO PE Valuation
BBIO has no meaningful PE right now: it lost money over the past year.
BBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BBIO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.04 | +$1.17 |
| Q2 2026 | -$3.57 | +$0.55 |
| Q1 2026 | -$3.74 | -$0.18 |
| Q4 2025 | -$3.78 | -$0.90 |
| Q3 2025 | -$4.21 | -$1.79 |
| Q2 2025 | -$4.12 | -$1.48 |
| Q1 2025 | -$3.56 | -$0.33 |
| Q4 2024 | -$2.88 | +$1.07 |
BBIO is still losing money, but less than at its worst: $3.04 per share over the past year, against $4.21 at its worst in late 2025.
BBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $353.2M | +193% |
| Q2 2026 | $243.7M | +120% |
| Q1 2026 | $194.5M | +67% |
| Q4 2025 | $154.2M | +2521% |
| Q3 2025 | $120.7M | +4318% |
| Q2 2025 | $110.6M | +5000% |
| Q1 2025 | $116.6M | -45% |
| Q4 2024 | $5.9M | +237% |
BBIO's revenue has grown year over year for six quarters in a row: $353M last quarter, up 193% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.3% | +117 points |
| Q2 2026 | -44% | +78 points |
| Q1 2026 | -54% | +35 points |
| Q4 2025 | -91% | +3752 points |
| Q3 2025 | -120% | +6898 points |
| Q2 2025 | -121% | +7975 points |
| Q1 2025 | -89% | -90 points |
| Q4 2024 | -3843% | +6324 points |
BBIO's operating margin was −3.3% last quarter, up 117 points from the same quarter a year ago, near the top of its range since 2019.
BBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$44.5M | +$65.6M |
| Q2 2026 | -$71.5M | +$9.7M |
| Q1 2026 | -$197.3M | +$1.9M |
| Q4 2025 | -$56.5M | +$138.9M |
| Q3 2025 | -$110M | +$70.7M |
| Q2 2025 | -$81.3M | -209% |
| Q1 2025 | -$199.2M | +$21M |
| Q4 2024 | -$195.4M | -$70.1M |
BBIO has burned cash in almost every quarter: −$370M over the past year, against −$586M the year before.
BBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +244K shares |
| 1 year | +2.2% | +4.2M shares |
| 3 years | +20% | +32.7M shares |
| 5 years | +34% | +49.4M shares |
| Available history | +87% | +90.9M shares |
BBIO has 196M diluted shares, up 2.2% from a year ago, despite $253M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $42.5M |
| Q2 2026 | $127.5M |
| Q1 2026 | $82.5M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $48.3M |
| Q4 2021 | $1.5M |
BBIO spent $253M buying back its own shares over the past year.
BBIO Net Leverage
BBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 48.6 | Neutral |
BBIO's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
BBIO PE vs Healthcare Sector
BBIO has no meaningful PE right now: it lost money over the past year.
BBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $70.1 | 12% above |
| 20 week MA | $75.3 | 3.9% above |
| 50 week MA | $73.0 | 7.1% above |
| 100 week MA | $58.0 | 35% above |
| 200 week MA | $41.6 | 88% above |
BBIO is in an uptrend: it's above all five of its weekly moving averages, and 88% above its 200-week average.
BBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.8 | $69.5 | +89% |
| 2021 | $69.5 | $40.6 | -42% |
| 2022 | $40.6 | $7.88 | -81% |
| 2023 | $7.88 | $40.4 | +412% |
| 2024 | $40.4 | $28.0 | -31% |
| 2025 | $28.0 | $75.8 | +171% |
| 2026 YTD | $75.8 | $78.2 | +3.1% |
BBIO's yearly returns have swung widely, from +412% in 2023 to −81% in 2022. It's up 3.1% so far in 2026.